iData Research thoroughly covers the orthopedic device market, providing in-depth analysis of the trends that are shaping the industry, updates on new and emerging technology, and much more. We not only provide a comprehensive orthopedic industry overview, but we also delve deep into sub-categories such as the extremities market, joint reconstruction market, arthroplasty market and many others.
Companies of all sizes have turned to iData for more than a decade as they look for the information that will help them take the action necessary to help ensure continued profitability.
The very first bone stimulator device in Canada received Health Canada license in November 1999. As of 2015 there were a total of seven players in the long bone growth stimulator market, three of which also had either a separate device for spinal application or had their only device also indicated for spine. For the purpose of this report, estimated units were separated by indication and only long bone (i.e. fractures) related units were included. There is a brief discussion regarding the break-down between long bone and spinal units in the Electrical Stimulator Market section and under the competitive analysis section. For context, the long bone market is estimated to be more than seven times bigger than spine ($8.0 vs. $1.1 million, respectively) as of 2015. There is also a brief discussion on the estimated break-down between units sold and units rented under the Ultrasonic Stimulator Market section and under the competitive analysis section.
One of the market limiters for the Canadian HA market is the reimbursement structure. None of the products are covered under standard healthcare plans and must be purchased directly or through extended healthcare coverage or private insurance. Thus, some patients opt out to receiving cortisone injections; these are reimbursed by standard healthcare and are a more affordable choice.
One of the factors that contributed positively to this market is ever expanding indication. The market originally started with treating osteoarthritis (OA) of the knee, since then some products expanded into hip, shoulder, a number of small joints, as well as assisting with post-surgery joint recovery.
Bone graft substitute products are utilized by dentists/periodontitis, neurosurgeons and orthopedic surgeons. Orthopedic indications represent the most major portion of the bone graft substitute market, with spinal fusions representing the most major category of surgery within that realm. For the purpose of this report, we do not assess the dental bone graft substitute market in any way. Instead, we focus on spinal indications for bone grafts and its size relative to the bone graft substitute market (excluding dental indications).